Zong Hai Li
Chief Executive Officer chez CARSGEN THERAPEUTICS HOLDINGS LIMITED
Fortune : 166 M $ au 31/03/2024
Profil
Zong Hai Li a fondé CARsgen Therapeutics Holdings Ltd. et CARsgen Therapeutics Co. Ltd. Il est président, directeur général et scientifique de CARsgen Therapeutics Holdings Ltd. et président et directeur général de CARsgen Therapeutics Co. Ltd. Le Dr Li a précédemment occupé le poste de professeur à l'Institut du cancer de Shanghai et de professeur à l'hôpital Renji. Il a obtenu un diplôme de premier cycle et un diplôme d'études supérieures de l'hôpital Xiangya de l'Université centrale du Sud.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 30/06/2023 | 215 572 730 ( 37,45% ) | 166 M $ | 31/03/2024 |
Postes actifs de Zong Hai Li
| Sociétés | Poste | Début |
|---|---|---|
| CARSGEN THERAPEUTICS HOLDINGS LIMITED | Chief Executive Officer | 01/02/2021 |
CARsgen Therapeutics Co. Ltd.
 CARsgen Therapeutics Co. Ltd. BiotechnologyHealth Technology CARsgen Therapeutics Co., Ltd. develops an immunotherapy cancer treatment. It develops a novel cell-based immunotherapy using T-cells carrying chimeric antigen receptor technology for cancer treatment. The company was founded by ZongHai Li in 2014 and is headquartered in Shanghai, China. | Chief Executive Officer | 30/10/2014 |
Anciens postes connus de Zong Hai Li
| Sociétés | Poste | Fin |
|---|---|---|
Guilin Pavay Gene Pharmaceutical Co. Ltd.
 Guilin Pavay Gene Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Hua Han Health Industry Holdings Ltd., Guilin Pavay Gene Pharmaceutical Co. Ltd. is a private company that manufactures and distributes pharmaceutical products. The company is based in Guilin, China. | Corporate Officer/Principal | 01/04/2002 |
Renji Hospital
 Renji Hospital Hospital/Nursing ManagementHealth Services Renji Hospital, located in Huangpu, China, was built in 1844 and has a history of over 170 years. It is a comprehensive 3A hospital with a complete range of disciplines, integrating medical treatment, teaching, and scientific research. Renji Hospital was the first medical institution in China to carry out clinical and scientific research on assisted reproductive technology and has become the quality control center for assisted reproductive technology since 2018. The hospital has five areas in total and has a timeline of development process. | Corporate Officer/Principal | - |
| The Shanghai Cancer Institute | Corporate Officer/Principal | - |
Formation de Zong Hai Li
| Xiangya Hospital Central South University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CARSGEN THERAPEUTICS HOLDINGS LIMITED | Health Technology |
| Entreprise privées | 4 |
|---|---|
Guilin Pavay Gene Pharmaceutical Co. Ltd.
Guilin Pavay Gene Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Hua Han Health Industry Holdings Ltd., Guilin Pavay Gene Pharmaceutical Co. Ltd. is a private company that manufactures and distributes pharmaceutical products. The company is based in Guilin, China. | Health Technology |
| The Shanghai Cancer Institute | |
CARsgen Therapeutics Co. Ltd.
CARsgen Therapeutics Co. Ltd. BiotechnologyHealth Technology CARsgen Therapeutics Co., Ltd. develops an immunotherapy cancer treatment. It develops a novel cell-based immunotherapy using T-cells carrying chimeric antigen receptor technology for cancer treatment. The company was founded by ZongHai Li in 2014 and is headquartered in Shanghai, China. | Health Technology |
Renji Hospital
Renji Hospital Hospital/Nursing ManagementHealth Services Renji Hospital, located in Huangpu, China, was built in 1844 and has a history of over 170 years. It is a comprehensive 3A hospital with a complete range of disciplines, integrating medical treatment, teaching, and scientific research. Renji Hospital was the first medical institution in China to carry out clinical and scientific research on assisted reproductive technology and has become the quality control center for assisted reproductive technology since 2018. The hospital has five areas in total and has a timeline of development process. | Health Services |
